Cited by 2,435HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentHIV Research and Treatment

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Open access

Abdool Karim, Quarraisha, Abdool Karim, Salim S., Frohlich, Janet A., Grobler, Anneke C., Baxter, Cheryl, Mansoor, Leila E., Kharsany, Ayesha B. M., Sibeko, Sengeziwe, Mlisana, Koleka P., Omar, Zaheen, Gengiah, Tanuja N., Maarschalk, Silvia, Arulappan, Natasha, Mlotshwa, Mukelisiwe, Morris, Lynn, Taylor, Douglas, on behalf of the CAPRISA 004 Trial Group·2010·Science

DOI 10.1126/science.1193748PMC PMC3001187

Open this paper in CoChat — free account

Abstract

The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide reverse transcriptase inhibitor, for the prevention of HIV acquisition in women. A double-blind, randomized controlled trial was conducted comparing tenofovir gel (n = 445 women) with placebo gel (n = 444 women) in sexually active, HIV-uninfected 18- to 40-year-old women in urban and rural KwaZulu-Natal, South Africa. HIV serostatus, safety, sexual behavior, and gel and condom use were assessed at monthly follow-up visits for 30 months. HIV incidence in the tenofovir gel arm was 5.6 per 100 women-years (person time of study observation) (38 out of 680.6 women-years) compared with 9.1 per 100 women-years (60 out of 660.7 women-years) in the placebo gel arm (incidence rate ratio = 0.61; P = 0.017). In high adherers (gel adherence > 80%), HIV incidence was 54% lower (P = 0.025) in the tenofovir gel arm. In intermediate adherers (gel adherence 50 to 80%) and low adherers (gel adherence < 50%), the HIV incidence reduction was 38 and 28%, respectively. Tenofovir gel reduced HIV acquisition by an estimated 39% overall, and by 54% in women with high gel adherence. No increase in the overall adverse event rates was observed. There were no changes in viral load and no tenofovir resistance in HIV seroconverters. Tenofovir gel could potentially fill an important HIV prevention gap, especially for women unable to successfully negotiate mutual monogamy or condom use.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/science.1193748

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180580 · Cited by 15,291
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks‐Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M. S., Adams, E. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,036
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial.
Auvert, B., Taljaard, D., Lagarde, E., Sobngwi-Tambekou, J., Sitta, R., & Puren, A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020298 · Cited by 2,451
Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.
Bailey, R. C., Moses, S., Parker, C. B., Agot, K., Maclean, I., Krieger, J. N., Williams, C. F., Campbell, R. T., & Ndinya-Achola, J. O. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60312-2 · Cited by 2,292
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.
Gray, R. H., Kigozi, G., Serwadda, D., Makumbi, F., Watya, S., Nalugoda, F., Kiwanuka, N., Moulton, L. H., Chaudhary, M. A., Chen, M. Z., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60313-4 · Cited by 2,226
Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial
Grosskurth, H., Todd, J., Mwijarubi, E., Mayaud, P., Nicoll, A., ka-Gina, G., Newell, J., Grosskurth, H., Todd, J., Mayaud, P., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91380-7 · Cited by 1,387
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial
Damme, L. V., Gita Ramjee, H., Alary, M., Vuylsteke, B., Chandeying, V., Rees, H., Sirivongrangson, P., Mukenge-Tshibaka, L., Ettiègne-Traoré, V., Uaheowitchai, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11079-8 · Cited by 796
Prevention of SIV Infection in Macaques by ( R )-9-(2-Phosphonylmethoxypropyl)adenine
Tsai, C., Follis, K. E., Sabó, A., Beck, T. W., Grant, R., Bischofberger, N., Benveniste, R. Ė., & Black, R. J. (1995) · Science · doi:10.1126/science.270.5239.1197 · Cited by 563
HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response
Karim, S. S. A., Churchyard, G., Karim, Q. A., & Lawn, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60916-8 · Cited by 544

Show all 33 references

Research works printed but not linked: 1

R. S. Brown D. Goodwin S. Zhang E. Fagan paper presented at the 13th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD) Washington DC 20 to 24 March 2009.

Sorted by citations

Items 701–800 of 1,005

Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection
Date, A. A., Shibata, A., Mcmullen, E., Bruzzo, K. L., Bruck, P. T., Belshan, M., Zhou, Y., & Destache, C. J. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2015.1942 · Cited by 35
MiniCD4 Microbicide Prevents HIV Infection of Human Mucosal Explants and Vaginal Transmission of SHIV162P3 in Cynomolgus Macaques
Dereuddre‐Bosquet, N., Morellato, L., Brouwers, J., Augustijns, P., Bouchemal, K., Ponchel, G., Ramos, O. H. P., Herrera, C., Stefanidou, M., Shattock, R. J., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1003071 · Cited by 35
Compartmentalized Accumulation of cAMP near Complexes of Multidrug Resistance Protein 4 (MRP4) and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Contributes to Drug-induced Diarrhea
Moon, C., Zhang, W., Ren, A., Arora, K., Sinha, C., Yarlagadda, S., Woodrooffe, K., Schuetz, J. D., Valasani, K. R., de Jonge, H. R., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.605410 · Cited by 35
Beyond HIV microbicides: multipurpose prevention technology products
Malcolm, K. R., Boyd, P., McCoy, C., & Murphy, D. J. (2014) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.12852 · Cited by 35
Apparent declining efficacy in randomized trials
O’Hagan, J. J., Hernán, M. Á., Walensky, R. P., & Lipsitch, M. (2011) · AIDS · doi:10.1097/qad.0b013e32834e1ce7 · Cited by 35
What Primary Care Providers Need to Know About Preexposure Prophylaxis for HIV Prevention
Krakower, D., & Mayer, K. H. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-7-201210020-00510 · Cited by 36
Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?
Verguet, S., Stalcup, M., & Walsh, J. A. (2013) · Sexually Transmitted Infections · doi:10.1136/sextrans-2012-050891 · Cited by 35
The rapidly changing paradigm of HIV prevention: time to strengthen social and behavioural approaches
de Wit, J. B. F., Aggleton, P., Myers, T., & Crewe, M. (2011) · Health Education Research · doi:10.1093/her/cyr021 · Cited by 36
Natural polyphenols: potential in the prevention of sexually transmitted viral infections
Date, A. A., & Destache, C. J. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.10.019 · Cited by 35
A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges
Kovářová, M., Swanson, M. D., Sánchez, R. I., Baker, C., Steve, J., Spagnuolo, R. A., Howell, B. J., Hazuda, D. J., & Garcia, J. V. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw042 · Cited by 36
Amyloid formation: functional friend or fearful foe?
Bergman, P., Roan, N. R., Römling, U., Bevins, C. L., & Münch, J. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12479 · Cited by 35
Prioritizing Risk in Preparation for a Demonstration Project: A Mixed Methods Feasibility Study of Oral Pre-Exposure Prophylaxis (PREP) among Female Sex Workers in South India
Reza‐Paul, S., Lazarus, L., Doshi, M., Rahman, S. H. U., Ramaiah, M., Maiya, R., Venugopal, M. S., Venukumar, K. T., Sundararaman, S., Becker, M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166889 · Cited by 35
The cost‐effectiveness of multi‐purpose HIV and pregnancy prevention technologies in South Africa
Quaife, M., Terris‐Prestholt, F., Eakle, R., Escobar, M. A. C., Kilbourne‐Brook, M., Mvundura, M., Meyer‐Rath, G., Delany‐Moretlwe, S., & Vickerman, P. T. (2018) · Journal of the International AIDS Society · doi:10.1002/jia2.25064 · Cited by 35
Residual T cell activation and skewed CD8+ T cell memory differentiation despite antiretroviral therapy-induced HIV suppression
Tanko, R. F., Soares, A. P., Masson, L., Garrett, N., Samsunder, N., Karim, Q. A., Karim, S. S. A., Riou, C., & Burgers, W. A. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.06.001 · Cited by 35
Topical Inserts: A Versatile Delivery Form for HIV Prevention
Peet, M. M., Agrahari, V., Anderson, S. M., Hanif, H., Singh, O., Thurman, A. R., Doncel, G. F., & Clark, M. R. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11080374 · Cited by 35
Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery
Hu, M., Patel, S. K., Zhou, T., & Rohan, L. C. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.018 · Cited by 35
Pharmacists as providers of HIV pre-exposure prophylaxis
Bruno, C. B., & Saberi, P. (2012) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-012-9709-0 · Cited by 36
Engineering a degradable polyurethane intravaginal ring for sustained delivery of dapivirine
Kaur, M., Gupta, K. M., Poursaid, A. E., Karra, P., Mahalingam, A., Aliyar, H. A., & Kiser, P. F. (2011) · Drug Delivery and Translational Research · doi:10.1007/s13346-011-0027-1 · Cited by 35
HIV Postexposure Prophylaxis in an Urban Population of Female Sex Workers in Nairobi, Kenya
Izulla, P., McKinnon, L. R., Munyao, J., Karanja, S., Koima, W. J., Parmeres, J., Kamuti, S., Kioko, R. M., Nagelkerke, N. J. D., Gakii, G., et al. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318278ba1b · Cited by 35
Evaluation of microporous polycaprolactone matrices for controlled delivery of antiviral microbicides to the female genital tract
Asvadi, N. H., Dang, N., Davis-Poynter, N. J., & Coombes, A. G. A. (2013) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-013-5010-6 · Cited by 35
Preexposure Prophylaxis (PrEP) for HIV Prevention: The Primary Care Perspective
Conniff, J., & Evensen, A. (2016) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2016.01.150223 · Cited by 35
Evaluation of poly(lactic-co-glycolic acid) and poly( dl -lactide-co-ε-caprolactone) electrospun fibers for the treatment of HSV-2 infection
Aniagyei, S. E., Sims, L. B., Malik, D. A., Tyo, K. M., Curry, K. C., Kim, W., Hodge, D. A., Duan, J., & Steinbach-Rankins, J. M. (2016) · Materials Science and Engineering C · doi:10.1016/j.msec.2016.11.029 · Cited by 35
The promise and peril of pre-exposure prophylaxis (PrEP): using social science to inform prep interventions among female sex workers.
Syvertsen, J. L., Bazzi, A. R., Scheibe, A. P., Adebajo, S. B., Strathdee, S. A., & Wechsberg, W. M. (2014) · African Journal of Reproductive Health · Cited by 34
MCRs reshaped into a switchable microwave-assisted protocol toward 5-aminoimidazoles and dihydrotriazines
Bell, C. E., Shaw, A. Y., Moliner, F. D., & Hulme, C. (2013) · Tetrahedron · doi:10.1016/j.tet.2013.11.035 · Cited by 34
MABGEL 1: First Phase 1 Trial of the Anti-HIV-1 Monoclonal Antibodies 2F5, 4E10 and 2G12 as a Vaginal Microbicide
Morris, G. C., Wiggins, R. C., Woodhall, S. C., Bland, M., Taylor, C. R., Jespers, V., Vcelar, B. A., & Lacey, C. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116153 · Cited by 34
Peptide-Derivatized SB105-A10 Dendrimer Inhibits the Infectivity of R5 and X4 HIV-1 Strains in Primary PBMCs and Cervicovaginal Histocultures
Bon, I., Lembo, D., Rusnati, M., Clò, A., Morini, S., Miserocchi, A., Bugatti, A., Grigolon, S., Musumeci, G., Landolfo, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076482 · Cited by 34
Safety and efficacy of tenofovir/IQP-0528 combination gels – A dual compartment microbicide for HIV-1 prevention
Dezzutti, C. S., Shetler, C., Mahalingam, A., Ugaonkar, S. R., Gwozdz, G., Buckheit, K. W., & Buckheit, R. W. (2012) · Antiviral Research · doi:10.1016/j.antiviral.2012.08.004 · Cited by 34
"Now we are in a different time; various bad diseases have come." understanding men's acceptability of male circumcision for HIV prevention in a moderate prevalence setting
Kelly‐Hanku, A., Kupul, M., Fitzgerald, L., Aeno, H., Neo, J., Trumb, R. N., Siba, P., Kaldor, J. M., Vallely, A. J., & of the Male Circumcision Acceptability and Impact Study (MCAIS) team (2012) · BMC Public Health · doi:10.1186/1471-2458-12-67 · Cited by 34
Live Simian Immunodeficiency Virus Vaccine Correlate of Protection: Immune Complex–Inhibitory Fc Receptor Interactions That Reduce Target Cell Availability
Smith, A. J., Wietgrefe, S. W., Shang, L., Reilly, C., Southern, P. J., Perkey, K., Duan, L., Köhler, H., Müller, S., Robinson, J. E., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400822 · Cited by 34
Elements of Condom-Use Decision Making among South African Men Who Have Sex with Men
Siegler, A. J., de Voux, A., Phaswana-Mafuya, N. R., Bekker, L., Sullivan, P. S., Baral, S., Winskell, K., Kose, Z., Wirtz, A. L., & Stephenson, R. B. (2014) · Journal of the International Association of Providers of AIDS Care (JIAPAC) · doi:10.1177/2325957414535979 · Cited by 34
Designing Preclinical Perceptibility Measures to Evaluate Topical Vaginal Gel Formulations: Relating User Sensory Perceptions and Experiences to Formulation Properties
Morrow, K. M., Fava, J. L., Rosen, R. K., Vargas, S. E., Shaw, J. G., Kojic, E. M., Kiser, P. F., Friend, D. R., & and The Project LINK Study Te David F. Katz (2013) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2013.0099 · Cited by 34
Building young women’s knowledge and skills in female condom use: lessons learned from a South African intervention
Schuyler, A. C., Masvawure, T. B., Smit, J. A., Beksinska, M. E., Mabude, Z., Ngoloyi, C., & Mantell, J. E. (2016) · Health Education Research · doi:10.1093/her/cyw001 · Cited by 34
Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa
Glaubius, R. L., Hood, G., Penrose, K. J., Parikh, U. M., Mellors, J. W., Bendavid, E., & Abbas, U. L. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw321 · Cited by 34
Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures
Srinivasan, P., Moss, J. A., Gunawardana, M., Churchman, S. A., Yang, F., Dinh, C. T., Mitchell, J. M., Zhang, J., Fanter, R. K., Miller, C. S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157061 · Cited by 34
Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B)
Robinson, J. A., Marzinke, M. A., Bakshi, R. P., Fuchs, E. J., Radebaugh, C. L., Aung, W. S., Spiegel, H. M. L., Coleman, J. S., Rohan, L. C., & Hendrix, C. W. (2016) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2016.0040 · Cited by 34
HIV Pathogenesis in the Human Female Reproductive Tract
Rodríguez‐García, M., Connors, K. A., & Ghosh, M. (2021) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00546-1 · Cited by 36
CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women
Gengiah, T. N., Karim, Q. A., Harkoo, I., Mansoor, L. E., Yende‐Zuma, N., Radebe, P., Samsunder, N., Baxter, C., Maharaj, B., Baum, M. M., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-052880 · Cited by 34
Self-citation
The effect of surface tension on the gravity-driven thin film flow of Newtonian and power-law fluids
Hu, B., & Kieweg, S. L. (2012) · Computers & Fluids · doi:10.1016/j.compfluid.2012.05.009 · Cited by 34
Bayesian Spatial Semi-Parametric Modeling of HIV Variation in Kenya
Ngesa, O. O., Mwambi, H. G., & Achia, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103299 · Cited by 34
Cross-reactive broadly neutralizing antibodies: timing is everything
Euler, Z., & Schuitemaker, H. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00215 · Cited by 34
Contraceptive Choices, Pregnancy Rates, and Outcomes in a Microbicide Trial
Sibeko, S., Baxter, C., Yende‐Zuma, N., Karim, Q. A., & Karim, S. S. A. (2011) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31822be512 · Cited by 34
Self-citation
Preconception and Contraceptive Care for Women Living with HIV
Hoyt, M. J., Storm, D. S., Aaron, E. Z., & Anderson, J. (2012) · Infectious Diseases in Obstetrics and Gynecology · doi:10.1155/2012/604183 · Cited by 34
Determinants of HIV testing among Nigerian couples: a multilevel modelling approach
Lépine, A., Terris‐Prestholt, F., & Vickerman, P. T. (2014) · Health Policy and Planning · doi:10.1093/heapol/czu036 · Cited by 34
The Effect of Human Immunodeficiency Virus Prevention and Reproductive Health Text Messages on Human Immunodeficiency Virus Testing Among Young Women in Rural Kenya
Njuguna, N., Ngure, K., Mugo, N., Sambu, C., Sianyo, C., Gakuo, S., Irungu, E., Baeten, J. M., & Heffron, R. A. (2016) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000000450 · Cited by 34
Bioadhesive HPMC Gel Containing Gelatin Nanoparticles for Intravaginal Delivery of Tenofovir
Manna, S., Lakshmi, U., Racharla, M., Sinha, P., Kanthal, L. K., & Kumar, S. P. N. (2016) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2016.60804 · Cited by 34
Expression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral Drugs
Hijazi, K., Cuppone, A. M., Smith, K. A., Stincarelli, M. A., Makinde, J., Falco, G. D., Hold, G. L., Shattock, R. J., Kelly, C. G., Pozzi, G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131405 · Cited by 34
Meaning-making matters in product design: users’ sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings
Rosen, R. K., van den Berg, J. J., Vargas, S. E., Senocak, N., Shaw, J. G., Buckheit, R. W., Smith, K. A., & Guthrie, K. M. (2015) · Contraception · doi:10.1016/j.contraception.2015.08.007 · Cited by 33
Future strategies in microbicide development
Rosenberg, Z., & Devlin, B. (2012) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2012.02.001 · Cited by 33
“If I don’t use a condom … I would be stressed in my heart that I’ve done something wrong”: Routine Prevention Messages Preclude Safer Conception Counseling for HIV-Infected Men and Women in South Africa
Matthews, L. T., Moore, L., Milford, C., Greener, R. K., Mosery, F. N., Rifkin, R., Psaros, C., Safren, S. A., Harrison, A. D., Wilson, I. B., et al. (2015) · AIDS and Behavior · doi:10.1007/s10461-015-1026-x · Cited by 33
A Multi-Compartment Single and Multiple Dose Pharmacokinetic Comparison of Rectally Applied Tenofovir 1% Gel and Oral Tenofovir Disoproxil Fumarate
Yang, K.-H., Hendrix, C. W., Bumpus, N. N., Elliott, J. E., Tanner, K., Mauck, C. K., Cranston, R., McGowan, I., Richardson‐Harman, N., Anton, P. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106196 · Cited by 33
HIV and chemoprophylaxis, the importance of considering social structures alongside biomedical and behavioral intervention
Roberts, E. T., & Matthews, D. D. (2012) · Social Science & Medicine · doi:10.1016/j.socscimed.2012.02.016 · Cited by 34
Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis
Laeyendecker, O. B., Redd, A. D., Nason, M., Longosz, A. F., Karim, Q. A., Naranbhai, V., Garrett, N., Eshleman, S. H., Karim, S. S. A., & Quinn, T. C. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv110 · Cited by 33
Nanoparticle Incorporation of Melittin Reduces Sperm and Vaginal Epithelium Cytotoxicity
Jallouk, A. P., Moley, K. H., Omurtag, K., Hu, G., Lanza, G. M., Wickline, S. A., & Hood, J. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095411 · Cited by 33
HIV treatment for prevention
Ambrosioni, J., Calmy, A., & Hirschel, B. J. (2011) · Journal of the International AIDS Society · doi:10.1186/1758-2652-14-28 · Cited by 33
Post-use assay of vaginal rings (VRs) as a potential measure of clinical trial adherence
Spence, P., Nel, A. M., van Niekerk, N., Derrick, T., Wilder, S., & Devlin, B. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.03.023 · Cited by 33
Incidence of Herpes Simplex Virus Type 2 Infections in Africa: A Systematic Review
Rajagopal, S., Magaret, A., Mugo, N., & Wald, A. (2014) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofu043 · Cited by 33
Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
Ilomuanya, M. O., Hameedat, A. T., Akang, E. N., Ekama, S., Silva, B. O., & Akanmu, S. A. (2020) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-020-00093-3 · Cited by 33
A Systematic Review of the Social Network Strategy to Optimize HIV Testing in Key Populations to End the Epidemic in the United States
Stojanovski, K., Naja-Riese, G. M., King, E. J., & Fuchs, J. D. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03259-z · Cited by 33
Prospects for a globally effective HIV-1 vaccine
Excler, J., Robb, M. L., & Kim, J. H. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.03.059 · Cited by 33
Food Security in the Context of HIV: Towards Harmonized Definitions and Indicators
Anema, A., Fielden, S. J., Castleman, T., Grede, N., Heap, A. N., & Bloem, M. W. (2013) · AIDS and Behavior · doi:10.1007/s10461-013-0659-x · Cited by 37
Using Conjoint Analysis to Measure the Acceptability of Rectal Microbicides Among Men Who Have Sex with Men in Four South American Cities
Kinsler, J. J., Cunningham, W. E., Nureña, C. R., Nadjat-Haiem, C., Grinsztejn, B. G. J., Casapía, M., Montoya, O., Sánchez, J., & Galea, J. T. (2011) · AIDS and Behavior · doi:10.1007/s10461-011-0045-5 · Cited by 33
Quantitative Analysis of Microbicide Concentrations in Fluids, Gels and Tissues Using Confocal Raman Spectroscopy
Chuchuen, O., Henderson, M. H., Sykes, C., Kim, M. S., Kashuba, A. D. M., & Katz, D. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0085124 · Cited by 33
Preconception care: preventing and treating infections
Lassi, Z. S., Imam, A. M., Dean, S. V., & Bhutta, Z. A. (2014) · Reproductive Health · doi:10.1186/1742-4755-11-s3-s4 · Cited by 36
Breast Milk of HIV-Positive Mothers Has Potent and Species-Specific In Vivo HIV-Inhibitory Activity
Hafner, R., Baker, C., Spagnuolo, R. A., Stamper, L., Fouda, G. G., Permar, S. R., Hinde, K., Kuhn, L., Bode, L., Aldrovandi, G. M., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01702-15 · Cited by 33
Biomedical HIV Prevention Including Pre-exposure Prophylaxis and Opiate Agonist Therapy for Women Who Inject Drugs
Page, K. A., Tsui, J. I., Maher, L., Choopanya, K., Vanichseni, S., Mock, P. A., Celum, C., & Martin, M. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000641 · Cited by 34
Rapidly Biodegrading PLGA-Polyurethane Fibers for Sustained Release of Physicochemically Diverse Drugs
Blakney, A. K., Simonovsky, F. I., Suydam, I. T., Ratner, B. D., & Woodrow, K. A. (2016) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6b00346 · Cited by 33
Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives
Mahomed, S. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00152-22 · Cited by 37
Variations in microbicide gel acceptability among young women in the USA and Puerto Rico
Giguere, R., Carballo‐Diéguez, A., Ventuneac, A., Mabragaña, M., Dolezal, C. L., Chen, B. A., Kahn, J. A., Zimet, G. D., & McGowan, I. (2011) · Culture Health & Sexuality · doi:10.1080/13691058.2011.630099 · Cited by 32
“Set it and Forget it”: Women’s Perceptions and Opinions of Long-Acting Topical Vaginal Gels
van den Berg, J. J., Rosen, R. K., Bregman, D. E., Thompson, L. A., Jensen, K. M., Kiser, P. F., Katz, D. F., Buckheit, K. W., Buckheit, R. W., & Morrow, K. M. (2013) · AIDS and Behavior · doi:10.1007/s10461-013-0652-4 · Cited by 32
Mathematical Insights in Evaluating State Dependent Effectiveness of HIV Prevention Interventions
Zhao, Y., Dimitrov, D., Liu, H., & Kuang, Y. (2013) · Bulletin of Mathematical Biology · doi:10.1007/s11538-013-9824-7 · Cited by 32
The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK
McCormack, S., Fidler, S. J., & Fisher, M. (2012) · International Journal of STD & AIDS · doi:10.1258/ijsa.2011.051211 · Cited by 32
Clinical challenges in HIV/AIDS: Hints for advancing prevention and patient management strategies
Sued, O. G., Figueroa, M. I., & Cahn, P. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.016 · Cited by 32
Development of a multi-layered vaginal tablet containing dapivirine, levonorgestrel and acyclovir for use as a multipurpose prevention technology
McConville, C., Major, I., Devlin, B., & Brimer, A. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.05.003 · Cited by 32
Preexposure Prophylaxis Modality Preferences Among Men Who Have Sex With Men and Use Social Media in the United States
Hall, E. W., Heneine, W., Sanchez, T., Sineath, R. C., & Sullivan, P. S. (2016) · Journal of Medical Internet Research · doi:10.2196/jmir.5713 · Cited by 32
The New Public Health and STD/HIV Prevention
Aral, S. O., Fenton, K. A., & Lipshutz, J. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4526-5 · Cited by 32
Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model
Prathipati, P. K., Mandal, S., Pon, G., Vivekanandan, R., & Destache, C. J. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2255-7 · Cited by 32
Motivations and barriers to uptake and use of female-initiated, biomedical HIV prevention products in sub-Saharan Africa: an adapted meta-ethnography
Eakle, R., Bourne, A. H., Jarrett, C., Stadler, J., & Larson, H. J. (2017) · BMC Public Health · doi:10.1186/s12889-017-4959-3 · Cited by 32
Evaluation of degradation kinetics and physicochemical stability of tenofovir
Agrahari, V., Putty, S., Mathes, C., Murowchick, J. B., & Youan, B.-B. C. (2014) · Drug Testing and Analysis · doi:10.1002/dta.1656 · Cited by 32
Self-efficacy, medication beliefs and adherence to antiretroviral therapy by patients attending a health facility in Pretoria
Adefolalu, A. O., Nkosi, Z. Z., Olorunju, S. A. S., & Masemola, P. (2014) · South African Family Practice · doi:10.1080/20786190.2014.975476 · Cited by 32
Development of polyether urethane intravaginal rings for the sustained delivery of hydroxychloroquine
Ho, E. A., Chen, Y. A., Traoré, Y. L., Li, A., & Fowke, K. R. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s71352 · Cited by 32
Differential Glucocorticoid Receptor‐Mediated Effects on Immunomodulatory Gene Expression by Progestin Contraceptives: Implications for HIV ‐1 Pathogenesis
Hapgood, J. P., Ray, R. M., Govender, Y., Avenant, C., & Tomasicchio, M. (2014) · American Journal of Reproductive Immunology · doi:10.1111/aji.12214 · Cited by 32
A cross-sectional evaluation of the prevalence and associations of HIV among female sex workers in the Gambia
Peitzmeier, S. M., Mason, K. L., Ceesay, N., Diouf, D., Drame, F., Loum, J., & Baral, S. (2013) · International Journal of STD & AIDS · doi:10.1177/0956462413498858 · Cited by 32
Unexpected Inflammatory Effects of Intravaginal Gels (Universal Placebo Gel and Nonoxynol-9) on the Upper Female Reproductive Tract: A Randomized Crossover Study
Smith‐McCune, K., Chen, J. C., Greenblatt, R. M., Shanmugasundaram, U., Shacklett, B. L., Hilton, J. F., Johnson, B., Irwin, J. C., & Giudice, L. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129769 · Cited by 31
Biphasic Elimination of Tenofovir Diphosphate and Nonlinear Pharmacokinetics of Zidovudine Triphosphate in a Microdosing Study
Chen, J., Flexner, C. W., Liberman, R. G., Skipper, P. L., Louissaint, N. A., Tannenbaum, S. R., Hendrix, C. W., & Fuchs, E. J. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182717c98 · Cited by 31
Expression of Membrane Drug Efflux Transporters in the Sigmoid Colon of HIV‐Infected and Uninfected Men
Rosa, M. F. D., Robillard, K. R., Kim, C. J., Hoque, M. T., Kandel, G. P., Kovacs, C., Kaul, R., & Bendayan, R. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.132 · Cited by 31
Adherence in the CAPRISA 004 Tenofovir Gel Microbicide Trial
Mansoor, L. E., Karim, Q. A., Yende‐Zuma, N., MacQueen, K. M., Baxter, C., Madlala, B. T., Grobler, A. C., & Karim, S. S. A. (2014) · AIDS and Behavior · doi:10.1007/s10461-014-0751-x · Cited by 31
Self-citation
Microbicides: still a long road to success
Vanpouille, C., Arakelyan, A., & Margolis, L. B. (2012) · Trends in Microbiology · doi:10.1016/j.tim.2012.05.005 · Cited by 31
Daily Oral Emtricitabine/Tenofovir Preexposure Prophylaxis and Herpes Simplex Virus Type 2 among Men Who Have Sex with Men
Marcus, J. L., Glidden, D. V., McMahan, V., Lama, J. R., Mayer, K. H., Liu, A., Montoya, O., Casapía, M., Hoagland, B., & Grant, R. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091513 · Cited by 32
Using geospatial modelling to optimize the rollout of antiretroviral-based pre-exposure HIV interventions in Sub-Saharan Africa
Gerberry, D. J., Wagner, B. G., Garcia-Lerma, J. G., Heneine, W., & Blower, S. M. (2014) · Nature Communications · doi:10.1038/ncomms6454 · Cited by 31
Pharmacologic Opportunities for HIV Prevention
Nicol, M. R., & Kashuba, A. D. M. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.189 · Cited by 31
Pharmacokinetic and Safety Analyses of Tenofovir and Tenofovir-Emtricitabine Vaginal Tablets in Pigtailed Macaques
Pereira, L. E., Clark, M. R., Friend, D. R., Garber, D. A., McNicholl, J. M., Hendry, R. M., Doncel, G. F., & Smith, J. M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02336-13 · Cited by 31
An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides
Tong, P., Lu, Z., Chen, X., Wang, Q., Yu, F., Zou, P., Yu, X., Li, Y., Lu, L., Chen, Y.-H., et al. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt230 · Cited by 31
Recent update in HIV vaccine development
Shin, S. Y. (2016) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2016.5.1.6 · Cited by 34
Targeting the HIV Epidemic in South Africa: The Need for Testing and Linkage to Care in Emergency Departments
Hansoti, B., Mwinnyaa, G., Hahn, E., Rao, A., Black, J. M., Chen, V., Clark, K., Clarke, W. A., Eisenberg, A. L., Fernández, R. E., et al. (2019) · EClinicalMedicine · doi:10.1016/j.eclinm.2019.08.007 · Cited by 31
Vaginal microbiome-hormonal contraceptive interactions associate with the mucosal proteome and HIV acquisition
Noël‐Romas, L., Perner, M., Molatlhegi, R. P., Zuend, C. F., Mabhula, A., Hoger, S., Lamont, A., Birse, K., Berard, A. R., McCorrister, S. J., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1009097 · Cited by 31
A qualitative exploration to understand barriers and facilitators to daily oral PrEP uptake and sustained adherence among HIV‐negative women planning for or with pregnancy in rural Southwestern Uganda
Atukunda, E. C., Owembabazi, M., Pratt, M. C., Psaros, C., Muyindike, W. R., Chitneni, P. R., Bwana, M., Bangsberg, D. R., Haberer, J. E., Marrazzo, J. M., et al. (2022) · Journal of the International AIDS Society · doi:10.1002/jia2.25894 · Cited by 31
A social ecology of rectal microbicide acceptability among young men who have sex with men and transgender women in Thailand
Newman, P. A., Roungprakhon, S., & Tepjan, S. (2013) · Journal of the International AIDS Society · doi:10.7448/ias.16.1.18476 · Cited by 33
Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices
Terris‐Prestholt, F., Foss, A. M., Cox, A. P., Heise, L., Meyer‐Rath, G., Delany‐Moretlwe, S., Mertenskoetter, T., Rees, H., Vickerman, P. T., & Watts, C. H. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-14 · Cited by 31
Llama Antibody Fragments Have Good Potential for Application as HIV Type 1 Topical Microbicides
Gorlani, A., Brouwers, J., McConville, C., van der Bijl, P., Malcolm, K. R., Augustijns, P., Quigley, A. F., Weiss, R. A., de Haard, H., & Verrips, T. C. (2011) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2011.0133 · Cited by 31
No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults
Tan, D. H. S., Kaul, R., Raboud, J., & Walmsley, S. L. (2010) · AIDS · doi:10.1097/qad.0b013e328341ddf7 · Cited by 31

Authors: Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., Gengiah, T. N., Maarschalk, S., Arulappan, N., Mlotshwa, M., Morris, L., Taylor, D., & on behalf of the CAPRISA 004 Trial Group
Affiliations: Centre for the AIDS Program of Research in South Africa (CAPRISA), Durban 4013, South Africa.
Centre for the AIDS Programme of Research in South Africa (ZA)
National Institute for Communicable Diseases (ZA)
Family Health International 360 (US)
ORCID: Grobler, Anneke C.
Baxter, Cheryl
Mansoor, Leila E.
Kharsany, Ayesha B. M.
Sibeko, Sengeziwe
Mlisana, Koleka P.
Gengiah, Tanuja N.
Arulappan, Natasha
Morris, Lynn
Taylor, Douglas
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2010-09-03
Volume: 329
Issue: 5996
Pages: 1168-1174
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.1193748
PMC: PMC3001187
OpenAlex: W2146634980
Cited by: 2,435
References: 33
Citations by year: 2026: 13 · 2025: 27 · 2024: 29 · 2023: 27 · 2022: 43 · 2021: 81 · 2020: 65 · 2019: 81 · 2018: 106 · 2017: 150 · 2016: 182 · 2015: 212 · 2014: 292 · 2013: 328 · 2012: 385
FWCI: 229.92
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Figshare (submittedVersion, cc-by)
ResearchSpace (University of KwaZulu-Natal) (submittedVersion)
Columbia Academic Commons (Columbia University)
Funders: National Institute of Allergy and Infectious Diseases (U01AI046749, U01AI068633, U19AI051794, U01AI068619, AI 51794)
Fogarty International Center (D43TW000231)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: tenofovir gel, HIV prevention, microbicides, vaginal gel, women, HIV incidence, antiretroviral drugs, nucleotide reverse transcriptase inhibitors, HIV seroconversion, tenofovir resistance, sexual behavior, condom use
MeSH terms: Tenofovir, Adenine, Administration, Intravaginal, Adolescent, Adult, Anti-Infective Agents, Local, Double-Blind Method, Female, Humans, Patient Compliance, Pregnancy, Pregnancy Outcome, Rural Population, Sexual Behavior, South Africa, Urban Population, Vaginal Creams, Foams, and Jellies, HIV-1, HIV Infections, Incidence, Anti-HIV Agents, Viral Load, Drug Resistance, Viral, Young Adult, Organophosphonates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks